Organicell Regenerative Medicine, Inc. (OCEL) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Organicell Regenerative Medicine, Inc. (OCEL) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 49/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Organicell Regenerative Medicine, Inc. (OCEL) Gesundheitswesen & Pipeline-Uebersicht
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company developing biological therapeutics, primarily Zofin, for degenerative diseases. Zofin, derived from perinatal sources, is currently in Phase I/II clinical trials for COVID-19, positioning Organicell within the regenerative medicine sector alongside competitors like AMHV and ATHJF.
Investmentthese
Organicell Regenerative Medicine, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is approximately $0.02 billion, with a negative P/E ratio of -3.75, reflecting its current lack of profitability. The primary value driver is the potential success of Zofin in clinical trials, particularly its Phase I/II trial for COVID-19. Upcoming data releases from these trials will be critical catalysts. A gross margin of 81.6% indicates strong potential profitability if Zofin gains regulatory approval and achieves commercial success. However, the company's negative profit margin of -92.3% highlights the significant expenses associated with research and development. The stock's beta of 1.36 suggests higher volatility compared to the overall market. The company's success hinges on navigating the regulatory landscape and securing partnerships for manufacturing and distribution.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.02 billion reflects its small size and early stage of development.
- Negative P/E ratio of -3.75 indicates the company is currently unprofitable.
- Gross margin of 81.6% suggests strong potential profitability if products are successfully commercialized.
- Profit margin of -92.3% highlights significant R&D expenses and lack of revenue from product sales.
- Beta of 1.36 indicates higher volatility compared to the market average.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary technology in perinatal-derived biologics.
- Zofin in Phase I/II clinical trials for COVID-19.
- Research collaborations with reputable institutions.
- High gross margin potential (81.6%).
Schwaechen
- Negative profit margin (-92.3%).
- Limited revenue generation.
- Reliance on the success of Zofin.
- Small market capitalization.
Katalysatoren
- Upcoming: Data readout from Phase I/II clinical trials for Zofin in COVID-19 treatment expected in late 2026.
- Ongoing: Potential for securing government grants and funding for research and development.
- Ongoing: Progress in expanding Zofin's applications to other degenerative diseases.
- Ongoing: Strategic partnership discussions with larger pharmaceutical companies.
Risiken
- Potential: Failure of Zofin in clinical trials.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from established pharmaceutical companies with greater resources.
- Ongoing: Financial constraints and the need for additional funding to support operations.
- Ongoing: Risks associated with operating in the OTC market, including limited liquidity and disclosure.
Wachstumschancen
- Zofin Clinical Trial Success: The successful completion of Phase I/II clinical trials for Zofin in treating COVID-19 could lead to regulatory approval and commercialization. The global market for COVID-19 therapeutics remains significant, although evolving with vaccination efforts. Positive trial results would significantly increase Organicell's valuation and attract potential partnerships. Timeline: Data readout expected in late 2026.
- Expansion of Zofin to Other Indications: Organicell can explore Zofin's potential in treating other degenerative diseases beyond COVID-19. The regenerative medicine market for conditions like osteoarthritis, Alzheimer's disease, and cardiovascular diseases is substantial. Successful preclinical and clinical studies in these areas could broaden Zofin's market reach. Timeline: Preclinical studies ongoing, with potential clinical trials starting in 2027.
- Strategic Partnerships and Licensing Agreements: Partnering with larger pharmaceutical companies for manufacturing, distribution, and commercialization of Zofin can accelerate its market penetration. Licensing agreements in specific geographic regions or for specific indications can generate revenue and reduce financial risk. Timeline: Ongoing discussions, with potential agreements in 2026-2027.
- Government Grants and Funding: Securing government grants and funding for research and development can reduce Organicell's financial burden and support its clinical programs. Government agencies and foundations are increasingly investing in regenerative medicine research. Timeline: Ongoing applications, with potential awards in 2026.
- Development of New Biologic Therapeutics: Expanding the pipeline with new biologic therapeutics targeting other degenerative diseases can diversify Organicell's product portfolio and reduce its reliance on Zofin. This requires investment in research and development and the acquisition of new technologies or intellectual property. Timeline: Research and development ongoing, with potential new product candidates in 2028.
Chancen
- Expansion of Zofin to other degenerative diseases.
- Strategic partnerships for manufacturing and distribution.
- Government grants and funding for research.
- Development of new biologic therapeutics.
Risiken
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Financial constraints and need for additional funding.
Wettbewerbsvorteile
- Proprietary technology in deriving and manufacturing Zofin from perinatal sources.
- Intellectual property protection for Zofin and its therapeutic applications.
- Established research collaborations with the CDC and Oklahoma State University.
- First-mover advantage in developing perinatal-derived biologics for specific indications.
Ueber OCEL
Organicell Regenerative Medicine, Inc., founded in 2011 and headquartered in Miami, Florida, is a clinical-stage biopharmaceutical company dedicated to the development of biological therapeutics for treating degenerative diseases. Originally incorporated as Biotech Products Services and Research, Inc., the company rebranded to Organicell Regenerative Medicine, Inc. in June 2018 to better reflect its focus on regenerative medicine. The company's primary product candidate, Zofin, is an acellular, biologic therapeutic derived from perinatal sources. Zofin is manufactured to retain naturally occurring microRNAs without any additives or diluents. Currently, Zofin is undergoing Phase I/II clinical trials as a potential treatment for COVID-19. Beyond its therapeutic development, Organicell also provides education, advertising, and marketing services to medical, healthcare, anti-aging, and regenerative service providers. The company has established research collaborations, including an agreement with the Centers for Disease Control and Prevention (CDC) to investigate Zofin's anti-inflammatory and anti-infective properties in influenza models and an agreement with Oklahoma State University to assess Zofin's efficacy in treating respiratory diseases caused by viruses with pandemic potential.
Was das Unternehmen tut
- Develop biological therapeutics for degenerative diseases.
- Focus on acellular, biologic therapeutics derived from perinatal sources.
- Manufacture Zofin, a therapeutic retaining naturally occurring microRNAs.
- Conduct Phase I/II clinical trials for Zofin to treat COVID-19.
- Provide education, advertising, and marketing services to medical and healthcare providers.
- Collaborate with the CDC to study Zofin's effectiveness against influenza.
- Partner with Oklahoma State University to evaluate Zofin for respiratory diseases.
Geschaeftsmodell
- Develop and commercialize biological therapeutics for degenerative diseases.
- Generate revenue through potential sales of Zofin, pending regulatory approval.
- Provide education, advertising, and marketing services to healthcare providers.
- Seek research and development funding through grants and partnerships.
Branchenkontext
Organicell operates within the competitive biotechnology industry, focusing on regenerative medicine. The market for regenerative medicine is projected to experience substantial growth, driven by increasing demand for therapies addressing degenerative diseases and aging-related conditions. Companies like AMHV, ATHJF, EMMLF, GRAMF, and KMSTF also operate in this space, developing various regenerative therapies. Organicell's focus on perinatal-derived biologics differentiates it within the market. The industry is characterized by high research and development costs, stringent regulatory requirements, and a lengthy time-to-market for new therapies.
Wichtige Kunden
- Patients suffering from degenerative diseases, including COVID-19.
- Medical and healthcare providers seeking regenerative medicine solutions.
- Research institutions and government agencies interested in biological therapeutics.
Finanzdaten
Chart & Info
Organicell Regenerative Medicine, Inc. (OCEL) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer OCEL verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer OCEL.
Kursziele
Wall-Street-Kurszielanalyse fuer OCEL.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von OCEL auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Harry L. Leider FACPE,
CEO
Harry L. Leider brings extensive experience in healthcare management and leadership to Organicell. His background includes serving in executive roles at various healthcare organizations, focusing on strategic planning, operational efficiency, and business development. He is a Fellow of the American College of Physician Executives (FACPE), demonstrating his commitment to professional excellence in healthcare leadership. Leider's expertise encompasses areas such as healthcare delivery, managed care, and pharmaceutical services.
Erfolgsbilanz: Under Harry L. Leider's leadership, Organicell has focused on advancing the clinical development of Zofin and establishing strategic partnerships. Key milestones include initiating Phase I/II clinical trials for COVID-19 and securing research agreements with the CDC and Oklahoma State University. Leider has also overseen the company's efforts to expand its intellectual property portfolio and explore new therapeutic applications for its biologic therapeutics.
OCEL OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Organicell Regenerative Medicine, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, lower trading volume, and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to adhere to strict listing standards, potentially increasing investment risk.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight compared to exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Check for any legal or regulatory issues involving the company.
- Review the company's investor relations materials and press releases.
- Consult with a financial advisor before investing.
- Phase I/II clinical trials for Zofin.
- Research agreements with the CDC and Oklahoma State University.
- CEO with experience in healthcare management.
- Focus on developing biological therapeutics for degenerative diseases.
Was Anleger ueber Organicell Regenerative Medicine, Inc. (OCEL) wissen wollen
What are the key factors to evaluate for OCEL?
Organicell Regenerative Medicine, Inc. (OCEL) currently holds an AI score of 49/100, indicating low score. Key strength: Proprietary technology in perinatal-derived biologics.. Primary risk to monitor: Potential: Failure of Zofin in clinical trials.. This is not financial advice.
How frequently does OCEL data refresh on this page?
OCEL prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OCEL's recent stock price performance?
Recent price movement in Organicell Regenerative Medicine, Inc. (OCEL) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology in perinatal-derived biologics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OCEL overvalued or undervalued right now?
Determining whether Organicell Regenerative Medicine, Inc. (OCEL) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OCEL?
Before investing in Organicell Regenerative Medicine, Inc. (OCEL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OCEL to a portfolio?
Potential reasons to consider Organicell Regenerative Medicine, Inc. (OCEL) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary technology in perinatal-derived biologics.. Additionally: Zofin in Phase I/II clinical trials for COVID-19.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of OCEL?
Yes, most major brokerages offer fractional shares of Organicell Regenerative Medicine, Inc. (OCEL) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track OCEL's earnings and financial reports?
Organicell Regenerative Medicine, Inc. (OCEL) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for OCEL earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for OCEL.